Matt Wagar

We’re excited to launch our inaugural Journal Club designed especially for #residents but applicable to all physicians & health care providers with a deep dive into the evolving paradigms in #cervicalcancer care. Join us 08/20. bit.ly/4agtqSq #Brachytherapy

"This project confirms that we need to help disseminate guidelines and new research to providers of all specialties; publishing guidelines alone is not sufficient," said Dr. Gross, about recent paper co-authored with colleagues in the GRACE Center. More at buff.ly/hg2LJQn

UW Department of Ob-Gyn resident Dr. Kharmen Bharucha brought the poster "Progression free survival as a surrogate end point of overall survival in randomized controlled trials of ovarian cancer maintenance therapies" to the @ASCO annual meeting earlier this month!

@IJGConline Thank you all!!

Congratulations Matt!! 🥳

It's graduation week in the UW Department of Ob-Gyn! All week, we'll celebrate our incredible trainees and learn what's next in their careers. First up, Dr. Matt Wagar graduates from gynecologic oncology fellowship! @mattkwagar obgyn.wisc.edu/ob-gyn-departm…

🌟Dr. Kharmen Bharucha presenting our work on maintenance therapy clinical endpoints in ovarian cancer Ph. 3 trials at @ASCO this morning! Stop by and say 👋🏻 @WiscObGyn @IJGCfellows #ASCO2025

🌟Dr. Rachel Mojdehbakhsh presenting her work on US based endometrial measurements in p53abn endometrial cancer at the @GOG fellows forum this morning in Miami Beach! @WiscObGyn

BREAKING from @NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection. #Thrombosis #cancer @OncoAlert @Cihan_Ay_MD DOI: 10.1056/NEJMoa2416112

Faculty, fellows, and residents from the UW Department of Ob-Gyn helped shape the agenda, and shared their latest research at the 2025 @SGO_org Annual Meeting on Women's Cancer: obgyn.wisc.edu/ob-gyn-departm…

Excited about our JAMA Oncology study! Adding CHT to RT showed no OS benefit in intermediate-risk cervical cancer, aligning with GOG 263 (#SGO2025). Hope this helps refine guidelines & improve patient care. @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD

🌟That’s a wrap on another amazing @SGO_org annual meeting. Great seeing friends near and far and a great program🧬. See you all in San Juan! 🇨🇺

The Patient Advocate Hope Award Poster Walk brought researchers and advocates together for an insightful discussion on key gynecologic oncology research. Attendees were fully engaged—now, we wait to see who wins! #PatientAdvocacy #SGOMtg

⁦@AmanikaKumar⁩ decentralized trials: bringing clinical trials to the patients home. Exciting new frontier for modifiable factors to improve patient outcomes. ⁦@SGO_org⁩ ⁦@GYNCancer⁩ #sgomtg #SGO2025

How can we involve more rural patients in clinical trials? At the #SGOMtg, Kaylee Underkofler, MD from @UVAMedicine discusses barriers to rural clinical trial enrollment among both patients and providers and shares whether the perceptions of these barriers align. Conclusion & Future Directions: ◦ Mistrust does not equal lack of interest. ◦ Provider bias may be introduced when we assume a lack of interest. ◦ Development of a standard approach to clinical trial recruitment for all patients may eliminate bias and enhance inclusion. #MoffittSGO25 #SGO2025 #SGOAM2025 #MultipleYourImpact #ClinicalTrials

💉Dr. Jiang Fang reporting results from a Phase 3 RCT comparing pulse dose Act-D to IM MTX for low risk GTN. Higher CR rate and shorter time to therapy completion with Act-D, with similar grade of side effects. Will Act-D be first line for low risk GTN? @SGO_org @IJGConline

🌟Dr. Maya Gross of @ReadySetGyo presenting her data on delays in gyn onc referrals for patients with limited English proficiency. Opportunities to identify those at risk for care delays and increase support! @SGO_org @UWashOBGYN @WiscObGyn

☢️Dr. Linda Duska of @uvahealthnews presenting updated OS and PFS2 results from Keynote-A18. HR of 0.67 in favor of the addition of pembrolizumab to primary ChemoRT for local lay advanced cervical cancer. A new standard of care! @SGO_org @IJGConline @gynoncjnls

PRESS RELEASE: #SGO2025 Plenary - "NRG Oncology Trial Supports Radiotherapy Alone Following Radical Hysterectomy Should Remain the Standard of Care for Early-Stage, Intermediate-Risk Cervical Cancer" Read the release: ow.ly/zJp150Vi3o8

🧬Dr. Sang Young Ryu with results from GOG263-no OS benefit with the addition of cisplatin to adjuvant RT for patients meeting Sedlis criteria after Radical hysterectomy for early stage cervix cancer. Increased grade 3/4 AE’s with the addition of cisplatin! @SGO_org @NRGonc

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer @mattkwagar @umnmedschool #gyncsm onclive.com/view/immunothe…